| Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval 2004 Edition Contributor(s): Teicher, Beverly A. (Editor), Andrews, Paul A. (Editor) |
|
 |
ISBN: 1588292282 ISBN-13: 9781588292285 Publisher: Humana OUR PRICE: $208.99 Product Type: Hardcover Published: February 2004 Annotation: This thoroughly updated and expanded second edition of Beverly Teicher's widely used classic survey provides a step-by-step guide to anticancer drug development from initial design through FDA approval. The authors have included new material on the use of high throughput screening in industry, on specialized in vitro/in vivo procedures employed by the National Cancer Institute (NCI) in preclinical drug evaluations, and on nonclinical testing to support both human clinical trials, as well as trials of biologic oncology products. The chapters on phase I, II, and III clinical trials and on novel phase II clinical trial designs for targeted therapies have been significantly updated, along with those on cancer drug development in Europe, working with the NCI, and the FDA's role in cancer drug development and setting requirements for approval. |
| Additional Information |
| BISAC Categories: - Medical | Oncology - General - Medical | Pharmacy - Medical | Nursing - Oncology & Cancer |
| Dewey: 616.994 |
| LCCN: 2003024925 |
| Series: Cancer Drug Discovery & Development |
| Physical Information: 1.2" H x 10.1" W x 7.3" (2.20 lbs) 451 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of "antileukemia" agents, but that other tumor models would be needed to discover drugs active against solid tumors. |